Filing Details

Accession Number:
0001519749-21-000004
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-30 18:31:03
Reporting Period:
2021-03-29
Accepted Time:
2021-03-30 18:31:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
899923 Myriad Genetics Inc MYGN In Vitro & In Vivo Diagnostic Substances (2835) 870494517
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1519749 B. Jayne Hart 320 Wakara Way
Salt Lake City UT 84108
Chief People Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-29 28,000 $19.47 108,128 No 4 M Direct
Common Stock Disposition 2021-03-29 28,000 $30.00 80,128 No 4 S Direct
Common Stock Acquisiton 2021-03-29 21,966 $24.89 102,094 No 4 M Direct
Common Stock Disposition 2021-03-29 21,966 $30.00 80,128 No 4 S Direct
Common Stock Acquisiton 2021-03-29 8,034 $24.89 88,162 No 4 M Direct
Common Stock Disposition 2021-03-29 8,034 $30.00 80,128 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right to buy) Disposition 2021-03-29 8,034 $0.00 8,034 $24.89
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-03-29 28,000 $0.00 28,000 $19.47
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-03-29 21,966 $0.00 21,966 $24.89
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-05-25 No 4 M Direct
0 2021-09-13 No 4 M Direct
0 2021-05-25 No 4 M Direct
Footnotes
  1. The transactions on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. Represents shares of common stock received upon exercise of a stock option award.
  3. The shares subject to this option are fully vested and exercisable.